HIV treatment with antibodies for a cure in Africa
Part of Infections clinical trials.
This study tests if giving antibodies along with standard HIV medications can help control the virus without daily pills. It may lead to a functional cure for people living with HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and have not taken any HIV medications before (except PrEP or PEP, but not long-acting shots in the last 2 years).
- Your CD4 count is above 200 and your viral load is above 1000 copies/mL.
- You are willing to start HIV medications and later take a break from them under careful monitoring.
- If you can get pregnant or get someone pregnant, you agree to use effective birth control during the study.
- You do not have active hepatitis B or C, serious heart disease, or a history of severe allergic reactions.
- You have not received an HIV vaccine or experimental HIV antibody treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This trial tests two lab-made antibodies that may help control HIV without daily pills. It is for people who started HIV treatment very early and now take a break from their regular meds under close monitoring.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study tests whether combining immune checkpoint inhibitors with chidamide can help achieve a functional cure for HIV. It is for people living with HIV who are already on effective antiretroviral therapy and have a stable, well-controlled viral load.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This trial tests whether giving early neutralizing antibodies can help infants living with HIV control the virus better. It aims to improve their long-term health.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.